Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

ERR2208913

—

c32333e5-8f28-5e6f-8b5b-c90f2a49af39

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.700
  • INTERFERON_GAMMA_RESPONSE+0.700
  • ALLOGRAFT_REJECTION+0.600
  • IL6_JAK_STAT3_SIGNALING+0.500
  • COMPLEMENT+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • G2M_CHECKPOINT+0.200
  • HEME_METABOLISM+0.200
  • IL2_STAT5_SIGNALING+0.200
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200

Top 10 suppressed

  • ANGIOGENESIS-0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
  • MYC_TARGETS_V2-0.500
  • HEDGEHOG_SIGNALING-0.400
  • MYC_TARGETS_V1-0.400
  • NOTCH_SIGNALING-0.400
  • WNT_BETA_CATENIN_SIGNALING-0.400
  • GLYCOLYSIS-0.300
  • MYOGENESIS-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2208965
melanoma-umap@29
——0.928
2TCGA-A8-A08I-01A-11R-A00Z-07
breast-umap@18
—C0.871
3s0122145
melanoma-umap@29
——0.869
47d3b4d06-1249-4a85-a66a-387d4e2e2cb2
melanoma-umap@29
——0.867
520090401.Her2HRpos
breast-umap@18
—D0.866
6C3N-02234
lung-landscapes@6
—cohortA10.862
71f57edd1-3bc9-4eaf-8045-8984d5c7f148
melanoma-umap@29
——0.860
8BSR_02_0049_A5_S69
breast-umap@18
—D0.853
9aa5bae83-33a0-4b75-a52d-7ba53267f6d3
melanoma-umap@29
——0.849
10TCGA-62-A46U-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.843

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.700Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.700Idelalisib— uncovered
ALLOGRAFT_REJECTION0.600Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
HEME_METABOLISM0.200Temsirolimus— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
COAGULATION0.100Binimetinib— uncovered
E2F_TARGETS0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered
KRAS_SIGNALING_UP0.100Inavolisib— uncovered
PANCREAS_BETA_CELLS0.100Cobimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.100Inavolisib— uncovered